Aquestive Therapeutics, Inc. (AQST)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$3.66-3.68%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · AQST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 59.9% |
| Our one-year growth estimate | diamond | 30.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 29.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 11 industry peers · Company calendar date is not available
AQST — earnings miss
Dated 2026-11-03
Results of Operations and Financial Condition. On November 3, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the third quarter ended September 30, 2026 and provided an update on recent developments in its business. A copy of the Company’s press release and the attached financial schedules are attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this
Why it matters: Management has started launch work, including plans for about 75 field staff. The update can show whether those plans continue.
Supportive ifOn November 3, management confirms the plan for about 75 field staff and reports continued launch work.
Worry ifOn November 3, management cuts or delays the field staff plan, or says launch work has slowed.
Why it matters: The FDA set March 16, 2027, as its review goal date. Approval would clear a key step toward launch.
Supportive ifThe FDA approves Anaphylm by March 16, 2027, without asking for new studies or more data.
Worry ifThe FDA issues another complete response, asks for new studies, or misses the March 16, 2027 goal date.
Why it matters: Management reported Phase 1 completion, but the inputs give no later milestone. A new study step would show continued progress.
Supportive ifAquestive announces that the next AQST-108 study has started or reports its results.
Worry ifAquestive reports a delay, a study stop, or no next study milestone in its next update.
Why it matters: The guide is a clear test of the company’s current business. The supplied Q1 and Q2 revenue figures do not yet show full-year results.
Watch forAquestive reports full-year 2026 revenue of at least $46 million.
Also watch forAquestive reports full-year 2026 revenue below $46 million or cuts its guide below that level.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$242 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $523 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,544 loss on $10,000 · 55.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.